



### SUMMARY OF PRODUCT CHARACTERISTICS





#### **1. NAME OF THE MEDICINAL PRODUCT**

Whole Virion Inactivated Corona Virus Vaccine

### 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

This is a single or multidose vial and injected in intra-muscular route.

Each Single human dose (0.5 mL) contains

Whole Virion Inactivated Corona Virus Antigen 6 micrograms. produced using a Vero cell-based platform, that propagates the virus, expressing the viral spike (S) protein of SARS-CoV-2.

For the full list of excipients, see section 6.1

#### **3. PHARMACEUTICAL FORM**

The vaccine is a white translucent liquid and free from extraneous particulate matter containing 6  $\mu$ g of Whole Virion Inactivated Corona Virus Antigen (strain: NIV-2020-770) for injection (sterile), pH: 7.00 - 8.00.

#### 4. CLINICAL PARTICULARS

It is indicated for active immunization to prevent COVID-19 caused by SARS-CoV-2 virus, in individuals 18 years of age and older. The use of this vaccine should be in accordance with official recommendations. This vaccine is permitted for restricted use in Emergency situation in Clinical Trial mode, as per provisions of New Drugs and Clinical Trials Rules, 2019, under Drugs & Cosmetics Act 1940.

#### 4.1 Therapeutic indication

COVAXIN<sup>TM</sup> is indicated for active immunization against SARS-CoV-2 Virus infection for age  $\geq 18$  years.





#### 4.2 Posology and method of administration.

COVAXIN<sup>TM</sup> should be administered as two doses on Day 0 and Day 28. Method of administration: intramuscular injection (IM).

#### 4.3 Contraindications

- Hypersensitivity to any constituents of the vaccine.
- Pregnant and lactating mothers.
- During fever or severe infection.
- Individuals below 18 years.

### 4.4 Special warnings and precautions for use

- Do not administer intravenously, intradermally, or subcutaneously.
- Like all other vaccines, supervision and appropriate medical treatment should always be available to treat any anaphylactic reactions following immunization.
- The vaccine should remain under medical supervision for at least 30 minutes after vaccination.

Before use, COVAXIN<sup>TM</sup> should be shaken well to obtain a uniform, whitish translucent suspension. Vial should be visually checked for the presence of any particulate matter or other coloration, if any, prior to its administration. If in doubt, do not use the contents of the vial.

COVAXIN<sup>TM</sup> should not be mixed with other vaccines.

### 4.5 Interaction with other medicinal products.

Chloroquine and Corticosteroids as they may impair the antibody response.

### 4.6 Pregnancy and Lactation

Safety and effectiveness have not been established in pregnant women and in nursing mothers.





#### 4.7 Effects on ability to drive and use machines

No studies on the effect of COVAXIN<sup>TM</sup> on the ability to drive and use machines have been performed.

#### 4.8 Undesirable effects

#### **Clinical Trial Experience**

Safety of the COVAXIN<sup>TM</sup> vaccine was established in Phase 1 and Phase 2 studies.

Phase 1 clinical trial was conducted in India in 375 adult healthy volunteers. The most common local adverse event reported was Injection site Pain. The most common systemic adverse events reported were headache, followed by fatigue, fever, body ache, abdominal pain, nausea, and vomiting. The other less common adverse events were dizziness/giddiness, tremor, sweating, cold, cough, and injection site swelling. No vaccine related serious adverse events (SAE) were reported.

A Phase 2 clinical trial was conducted in India in 380 adolescents and adult healthy volunteers. Similar adverse events were reported in the phase 2 clinical trial. No serious adverse events (SAE) were reported.

A Phase 3 efficacy study is on-going in 25,800 participants and administered with 1<sup>st</sup> dose of vaccination with COVAXIN<sup>TM</sup>, no vaccine related adverse events were observed.

#### 4.9 Immune Response

COVID-19 disease is caused due to SARS-CoV-2 virus infection.

In Phase 1 clinical trial a total of 375 healthy participants were enrolled across the three groups and received three vaccine formulations, BBV152A ( $3\mu g$  with Algel-IMDG (Aluminium hydroxide gel- Imidazo quinolin gallamide (IMDG); a TLR 7/8 agonist), BBV152B ( $6\mu g$  with Algel-IMDG), and BBV152C ( $6\mu g$  with Algel). None of the participants had detectable neutralizing antibodies at baseline analyzed by MNT<sub>50</sub>. The proportion of participants seroconverted post 2 weeks after 2<sup>nd</sup> dose was 87.9%, 91.9%, and 82.8% in the BBV152A, B, and C groups, respectively.





In Phase 2 clinical trial a total of 380 healthy participants were enrolled among two groups and received two vaccine formulations, BBV152 A and BBV152B. None of the participants had detectable neutralizing antibodies at baseline analyzed by  $MNT_{50}$ . The proportion seroconverted participants of Group 1 and Group 2, post 4 weeks of 2<sup>nd</sup> dose was 88.0% and 96.6% respectively.

#### 4.10 Overdose

No case of overdose has been reported.

#### **5. PHARMACOLOGICAL PROPERTIES**

#### 5.1. Pharmacodynamic properties

COVID-19 disease is caused due to SARS-CoV-2 virus infection. **COVAXIN<sup>TM</sup>** is a whole virion inactivated SARS-CoV-2 virus vaccine, has been studied in Phase 1 and 2 clinical studies for safety and immunogenicity and found to be safe and immunogenic. **COVAXIN<sup>TM</sup>** has been shown to prevent COVID-19 following 2 doses given 4 weeks apart. The duration of protection against COVID-19 is currently unknown.

### 5.2 Pharmacokinetic properties

Evaluation of pharmacokinetic properties is not required for vaccines.

### 5.3 Preclinical safety data

All the formulations were tested for immunogenicity in mice, rats, and rabbits. Mice, rats, and rabbits were vaccinated on days 0, 7, and 14 (n+1 doses). Further these formulations are tested for immunogenicity, safety, and protective efficacy in Syrian Hamster challenge model and Non-Human Primates (*Rhesus macaque*) challenge model. The Hamsters were vaccinated on Days 0, 14, and 35 (n+1 doses), the live SARS-CoV-2 virus was challenged through intranasal route on Day 50. Likewise, the Rhesus macaques were vaccinated on Days 0 and 14, and live SARS-CoV-2 virus was challenged through intranasal routes on Day 28. All the formulations were found to be safe, immunogenic, and provided effective protection to both upper and lower respiratory tract.



## 

#### PHARMACEUTICAL PARTICULARS

#### 6.1 List of excipients and composition

Each 0.5 mL (single human dose) contains

Whole Virion Inactivated Corona Virus Antigen	6 µg
Aluminium hydroxide gel equivalent to Al <sup>+3</sup>	250 µg
TLR 7/8 Agonist	15 µg
2-phenoxyethanol	2.5 mg
Phosphate buffered saline	q.s. to 0.5 mL
Note: TLR 7/8 agonist is an Imidazo quinolin gallamide (IMDG)	

#### **6.2 Incompatibilities**

The product should not be mixed with any other medicinal products or active immunizing agents.

#### 6.3 Shelf life

The expiry date of COVAXIN<sup>TM</sup> is indicated on the label and carton of the product. Do not use the product after the expiration date shown on the label and carton of the product.

#### 6.4 Special precautions for storage

Store at  $+2^{\circ}$  to  $+8^{\circ}$ C, do not freeze. Discard if frozen.

Shake well before use. Keep out of reach of children. Protect from light.

Do not use the vaccine after the expiration date as shown on the label.

#### 6.5 Nature and contents of container

COVAXIN<sup>TM</sup> is presented as Single dose (0.5 mL) and multidose (5 mL and 10 mL) in transparent vial (type I glass) with a stopper (butyl rubber) and a flip-off plastic cap with aluminium seal. Each vial of single dose contains 0.5 mL, each vial of multidose contains 10 doses (5 mL) and 20 doses (10 mL) respectively.





#### 6.6 Handling of multi-dose vials

Opened vials should be used as soon as possible and within 6 hrs when kept between 2 - 8  $^{\circ}$ C.

#### Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

#### 7. THE VACCINE VIAL MONITOR (OPTIONAL)

#### Presentation available with or without vaccine vial monitor

Vaccine Vial Monitors (VVM7) dot is a part of the label on **COVAXIN<sup>TM</sup>** vials supplied through Bharat Biotech. VVM7 are supplied by TEMPTIME Corporation, USA. This is a time-temperature sensitive dot that provides an indication of the cumulative heat to which the vial has been exposed. It warns the end user when exposure to heat is likely to have degraded the vaccine beyond an acceptable level.

SE	DO NOT USE
51	DO NOT USE
A	A A
Square is	Square Square is darker
lighter than outer circle	circle than circle
The color of the inner square of the VVMs	Once a vaccine has reached or exceeded
begins with a shade that is lighter than the outer circle and continues to darken with time and/or exposure to heat.	DISCARD POINT the discard point, the colour of the inner square will be the same colour or darker than the outer circle.
unie and/or exposure to neat.	than the otter circle.
	Inform your supervisor





The interpretation of the VVM7 is simple: Focus on the central square; its colour will change progressively. As long as the colour of this square is lighter than the colour of the ring, the vaccine can be used. As soon as the colour of the central square is the same colour as the ring or of a darker colour than the ring, the vial should be discarded.

### 8. MARKETING AUTHORISATION NUMBER(S)

MF/BIO/21/000002, dated 3rd Jan, 2021

### 9. MARKETING AUTHORISATION HOLDER

Manufactured and Marketed by:



#### **Bharat Biotech International Ltd.**

Sy. No. 230, 231 and 235, Genome Valley, Turkapally, Shamirpet Mandal, Medchal-Malkajgiri District - 500 078, Telangana State, India.
E-mail: <u>feedback@bharatbiotech.com</u>; Website: <u>www.bharatbiotech.com</u>
For complaints and suggestions about the product, and any adverse event, please email to <u>feedback@bharatbiotech.com</u> or call on Toll-free number: 1800 102 2245

### **10. DATE OF CREATION / REVISION OF THE TEXT**

15<sup>th</sup> January, 2021

For use only of a Registered Medical Practitioner or Hospital or Laboratory Whole-Virion,

Inactivated Corona Virus Vaccine COVAXIN

1. NAME AND DESCRIPTION OF THE MEDICINAL PRODUCT: COVXXIP<sup>®</sup> (Whole-Viron inactivated Corona Virus Mocone) as a white translucent liquid the fram particulais mather containing 6 more (Whole-Virons, Inactivated Corona Virus Artigentyman NV-2020-770). COVXXIP<sup>®</sup> can be administrated to the inclinituals ages ≥ 15 years.

2. QUALITATIVE AND QUANTITATIVE COMPOSITION: Eachdras of 0.5ml and 0.5ml

# Active legislationt Quandity Whole Writer, Inactivated Central Visus Antigen (Strain: NV-2023-770) 6 µg Inactive legislations 8 µg Automative Registrations 0.25 mg TUPRIDE Agrinit 15 µg 2-Phonespharbal (P) 2.5 mg

Phosphate Buffered Saline 3. PHARMACEUTICAL FORM: Starie liquid for injection

 CLINICAL PARTICULARS
 4. CLINICAL PARTICULARS
 4.1 Therapeutic indication
 COVAXIN<sup>®</sup> is indicated for active immunization against SARS-CoV-2 Virus infection for age ≥18years.

15 µg 2.5 mg 0.1.10 D.5 m

4.2 Posology and method of administration. COVAXM\* should be administered as two does on Day 0 and Day 28. Method of administration: Inframewalter nijedion (Mi). Once opened, multi-does each should be used as soon as possible and within 6 hours whom kept ab belower 24\*\*C.

- Al Contrainfications
   Hypersensitivity to any constituents of the vaccine.
   Pregrami and lactating methors.
   During fever or severe infoction.
   Individuals below 18 years.

- A Special water to jease
   A Special water mig and precautions for use
   Do not administer intravenously, intrademaly, or subcutaneously.
   Use all other vectories, supervision and appropriate modical relationst should always
  be available to heat any anaphylactic mactions following immunization.
   The vaccines though omain under modical supervision for all least 30 minutes after
   vaccination.
- Before use, COVAXIN<sup>®</sup> should be shaken well to obtain a uniform, whitish translusont auspension. Vial should be visually checked for the presence of any particulate matter or other coloration. If any, prior to its administration. If in doubt, do not use the contents of the used
- of the vial. COVAXIN<sup>®</sup> should not be mixed with other vaccines.

4.5 Interaction with other medicinal products. Chloroquine and Confcostantids as they may impair the antibody response.

4.6 Pregnancy and Lactation Safety and effectiveness has not been established in pregnant women and in nursing

4.7 Effects on ability to drive and use machines No studies on the effect of COVAXIN<sup>®</sup> on the ability to drive and use tractines has been performed.

been performed. As Underlinelie effects Clinical Trial Experience Safety Orthe COVANN<sup>®</sup> secone was established in Phase 1 and Phase 2 studies. Phase 1 clinical trial was conducted in hofs in 375 skult healthy volunteers. The most common local advance event responded was injections bit Pran. The most common systemic advance events responded was injections bits Pran. The most common system dark, nausea, and voimilling. The other less common advance events responded dozieneskystems event responded was injections sommon advance events dozieneskystems, termor, weaking, coli, cough, and rejection site weiling. Ho vacches trading and under events (ASE) were sported.

A Phase 2 dirical trial was conducted in India in 380 adolescents and adult healthy viculaters, Schifter advance events were reported in the phase 2 dirical trial. No serious advance events (SAE) were reported.

A Phase 3 officery study is on-going in 25800 participants and administered with 1° does of vectination with BBV1528 (COVAUN®), no vaccine related adverse events were

Converse. 43 Immune Response COVID-19 disease is caused due to SARS-COV2 wrus infection. In Phase 1 circuital Irial a total of 37b healthy participants were encled across the three groups and received three vectors formulations, BBV1552 (Jug. With Algo-HMDG (Aluminium hydroxis gol: Imitation causelines against (MADG); IFIR 7B against BBV1552 (Hap with Algo-HMDG); and BBV1522 (Hap with Algo-Hkne of the partoparts and distribute numbering antifocations in bankins analysised (MADG); The proportion of partoparts services resolutions at the analysis was by 5%, b1.5%, and 82.5% in the BBV1520, BING, BI

the bor hart, a lartic groups, respectively. In Phase 2 clinical trial is claid of 300 benefity participants were enrolled among two groups and isolaved two vaccine formulations, BBV 152 A and BBV 152B. Nore of the participants had detectable neutralizing antibodies at baseline analyzed by MNT<sub>w</sub>. The proportion

seroconverted participants of Group 1 and Group 2, post 4 weeks of 2<sup>rd</sup> does was 88.0% and 98.6% respectively.

4.10 Overdose No case of overdose has been rep

no vase of precision are seen reported. 5. PHARMACO.COICAL, PROPERTIES 5.1. Pharmacodynamic properties COVID-19 disease in caused doe to SAR8-CoV-2 virus infection. COVAXIN<sup>®</sup> is a whol virtin inactivated SAR8-SoV-2 virus vectore, has been studied in Press 1 and 2 citetic addes for setty and mmunogeneity and found to be safe and emmonyance.COVAXIN has been shown to prevent COVID-19 following 2 cores given 4 weaks span. The durate of pelside/magnetic COVID-19 country uniform.

5.2 Pharmacokinetic properties Evaluation of pharmacokinetic properties is not required for vaccines.

Evaluation of pharmacickinstic properties is not required for vaccines. 5.3 Preclinical safety data Af the formulations were tested for immunogenicity in mice, rate, and rabble. Mice, rate, and rabble were vaccinated on days 9, 7, and 14 (in 1 doese). Further these formulations indicates the second of the second se

# and provided officative protection to both u 6,PHARMACEUTICAL PARTICULARS 6,1 List of exclipionts Austinum hydroxide gel TLR7/8 Agonist 2,Phenoxysthatol Phosphate Buffared Saline

6.2 Incompatibilities The product should not be mixed with any other medicinal products or active immunizing

sprime. 4.3 Shaff life The excit date of COVAXIN<sup>®</sup> is indicated on the label and varion of the product. Do not use the product after the expiration date shown on the label and carton of the product.

6.4 Special precautions for storage Store at 42° to +θ°C, do not hereas. Discard If frozen. Shake well before uses. Keep wild freach of children. Protectiform light Do not use the vaccine after the expiration date as shown on the label.

- COVACIN<sup>®</sup> is presented in USP type 1 glass. Single does visit -0 SmL Muth does visit -0 SmL (10 does) Muth does visit 10.0mL (20 does)

Mult does val = 10.5mt (20 doe) 8. Toe Vacciew Val Monitor ( Optisnal ) Presentation available with or without vaccine val monitor Vaccinu Val Monitore (VMM) dat is on the seal of the COVAXIN<sup>®</sup> vala supplied through Bharat Bolsch. VMM are supplied by TEMPTINE Corporation, USA. This is a time-temperature sensite doi That provides an Indication of the cumulative hast tell which the vala has been accessed. It warms the and user when access to head is likely to have degraded the vaccine tell world has accessible invel.



The interpretation of the VVM7 is simple: Focus on the central square; its colour will change progressively. As long as the colour of this square is lighter than the colour of the ring, the vaccine can be used. As soon as the colour of the central square is the same colour as the ring or of e deriver colour then the ring, the vial should be discarded.

21/020000

Revision date: January 2021 Manufactured & Marketed by:

200

BHARAT

Linkas Obstantikus. Baran Rossoki Instantistoval Linkad. Sy No. 200, 201 and 205. Simone Velley, Turkopaly, Stantager Mandal, Hylensbad, Matrinal-Mandager Distato - 200 270, Talangana State, India. E-mail leadeact globardoolach.com www.bharafoiolach.com

For complaints and suggestions about the product, and any adverse event, please emails feedbackgbbambiclass, core or call or Tall-free number. 1800, 192 2245